These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 9054961)

  • 21. Synthesis and topoisomerase II inhibitory and cytotoxic activity of oxiranylmethoxy- and thiiranylmethoxy-chalcone derivatives.
    Na Y; Nam JM
    Bioorg Med Chem Lett; 2011 Jan; 21(1):211-4. PubMed ID: 21115246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and biological evaluation of benzo[a]phenazine derivatives as a dual inhibitor of topoisomerase I and II.
    Zhuo ST; Li CY; Hu MH; Chen SB; Yao PF; Huang SL; Ou TM; Tan JH; An LK; Li D; Gu LQ; Huang ZS
    Org Biomol Chem; 2013 Jun; 11(24):3989-4005. PubMed ID: 23657605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Defective DNA topoisomerase II in ataxia-telangiectasia cells.
    Lavin MF; Singh SP
    Acta Biol Hung; 1990; 41(1-3):125-35. PubMed ID: 1965559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis, cytotoxicity, DNA binding and topoisomerase II inhibition of cassiarin A derivatives.
    Luesakul U; Palaga T; Krusong K; Ngamrojanavanich N; Vilaivan T; Puthong S; Muangsin N
    Bioorg Med Chem Lett; 2014 Jul; 24(13):2845-50. PubMed ID: 24835201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overproduction of topoisomerase II in an ataxia telangiectasia fibroblast cell line: comparison with a topoisomerase II-overproducing hamster cell mutant.
    Davies SM; Harris AL; Hickson ID
    Nucleic Acids Res; 1989 Feb; 17(4):1337-51. PubMed ID: 2537956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro assessment of novel transcription inhibitors and topoisomerase poisons in rhabdomyosarcoma cell lines.
    Wolf SJ; Wakelin LP; He Z; Stewart BW; Catchpoole DR
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1059-69. PubMed ID: 19277661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.
    Vispé S; Vandenberghe I; Robin M; Annereau JP; Créancier L; Pique V; Galy JP; Kruczynski A; Barret JM; Bailly C
    Biochem Pharmacol; 2007 Jun; 73(12):1863-72. PubMed ID: 17391647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and evaluation of novel ellipticines as potential anti-cancer agents.
    Deane FM; O'Sullivan EC; Maguire AR; Gilbert J; Sakoff JA; McCluskey A; McCarthy FO
    Org Biomol Chem; 2013 Feb; 11(8):1334-44. PubMed ID: 23314103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and cytotoxic properties of 4,11-bis[(aminoethyl)amino]anthra[2,3-b]thiophene-5,10-diones, novel analogues of antitumor anthracene-9,10-diones.
    Shchekotikhin AE; Glazunova VA; Dezhenkova LG; Luzikov YN; Sinkevich YB; Kovalenko LV; Buyanov VN; Balzarini J; Huang FC; Lin JJ; Huang HS; Shtil AA; Preobrazhenskaya MN
    Bioorg Med Chem; 2009 Mar; 17(5):1861-9. PubMed ID: 19208482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
    Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C
    Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 1-beta-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells.
    Loughlin S; Gandhi V; Plunkett W; Zwelling LA
    Cancer Chemother Pharmacol; 1996; 38(3):261-8. PubMed ID: 8646801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis, cytotoxicity and topoisomerase II inhibitory activity of lomefloxacin derivatives.
    Zhou Y; Xu X; Sun Y; Wang H; Sun H; You Q
    Bioorg Med Chem Lett; 2013 May; 23(10):2974-8. PubMed ID: 23566520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Yeast cells expressing differential levels of human or yeast DNA topoisomerase II: a potent tool for identification and characterization of topoisomerase II-targeting antitumour agents.
    van Hille B; Hill BT
    Cancer Chemother Pharmacol; 1998; 42(5):345-56. PubMed ID: 9771947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
    Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
    Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
    Bridewell DJ; Finlay GJ; Baguley BC
    Anticancer Drug Des; 2001 Dec; 16(6):317-24. PubMed ID: 12375884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation.
    Mansour OC; Evison BJ; Sleebs BE; Watson KG; Nudelman A; Rephaeli A; Buck DP; Collins JG; Bilardi RA; Phillips DR; Cutts SM
    J Med Chem; 2010 Oct; 53(19):6851-66. PubMed ID: 20860366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
    Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
    Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of the atypical protein kinase C zeta reduces topoisomerase II catalytic activity, cleavable complexes formation, and drug-induced cytotoxicity in monocytic U937 leukemia cells.
    Plo I; Hernandez H; Kohlhagen G; Lautier D; Pommier Y; Laurent G
    J Biol Chem; 2002 Aug; 277(35):31407-15. PubMed ID: 12105221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.